Advanced monobody CAR technology for Epha2 precision targeting of solid tumors gains international recognition
[by Ji, Yong Jun] Vaxcellbio announced on May 19 that it has officially registered a patent for a chimeric antigen receptor (CAR) technology based on monobody with the Japan Patent Office. This marks the company’s second Japanese patent within a month, following the recent registration of a patent for NK cell proliferation technology, representing the official recognition of two core immune cell therapy technologies in Japan.
This patent, co-developed by 안전한 바카라 사이트 and Chonnam National University, was domestically registered in April and is based on a monobody that selectively binds to ‘EphA2,’ a target protein overexpressed in solid tumors. The company noted that monobodies, with their simpler structure compared to conventional antibodies and ease of cellular expression, are gaining attention as a promising platform for next-generation CAR therapies.
안전한 바카라 사이트 intends to integrate this technology into its CAR therapy platform to advance the development of ‘VCB-1202 (development code),’ a next-generation CAR immune cell therapy candidate designed to secure both therapeutic efficacy and safety in the treatment of solid tumors.
“Japan is a globally competitive market in the field of anticancer immunotherapy, and this patent registration is a recognition of our company’s technological capabilities at an international level,” stated Lee Je-Jung, CEO of 안전한 바카라 사이트. “We will continue to set new benchmarks for solid cancer treatment and further strengthen our foundation for global commercialization.”
With this latest registration, 안전한 바카라 사이트 now holds a total of 15 patents (including 2 in Japan), with an additional 7 applications in Korea and 23 PCT international applications currently under review. The company plans to actively pursue open innovation strategies, including global licensing, as it continues to strengthen its intellectual property portfolio.